Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 162

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial

Open access
Lacroix, André, Gu, Feng, Gallardo, Wilson, Pivonello, Rosario, Yu, Yerong, Witek, Przemysław, Boscaro, Marco, Salvatori, Roberto, Yamada, Masanobu, Tauchmanova, Libuse, Roughton, Michael, Ravichandran, Shoba, Petersenn, Stephan, Biller, Beverly M K, Newell-Price, John, Arnaldi, Giorgio, Asha, Hesarghatta Shyamasunder, Bandgar, Tushar, Barkan, Ariel, Biering, Henrik, Bex, Marie, Bolanowski, Marek, Bronstein, Marcello Delano, Brue, Thierry, Bruera, Dario, Cavagnini, Francesco, Comlekci, Abdurrahman, De Block, Christophe, Delibasi, Tuncay, Fajardo-Montañana, Carmen, Feelders, Richard Abraham, Fleseriu, Maria, Gadelha, Monica Roberto, Geer, Eliza Brevoort, Heaney, Anthony, Houde, Ghislaine, Ichihara, Atsuhiro, Imran, Syed Ali, Ioachimescu, Adriana, Kadioglu, Pinar, Li, Yiming, Loli, Paola, Nishiyama, Mitsuru, Rozhinskaya, Liudmila, Ruchala, Marek, Saitoh, Youichi, Schöfl, Christof, Schopohl, Jochen, Shimatsu, Akira, Shimizu, Chikara, Snabboon, Thiti, Snyder, Peter, Suzaki, Noriyuki, Tabarin, Antoine, Takahashi, Yutaka, Britto, Susana Tara, T'Sjoen, Guy, Vantyghem, Marie-Christine, Velkeniers, Brigitte, Webb, Susan, Yamada, Shozo · 2018 · The Lancet Diabetes & Endocrinology

Abstract

BACKGROUND Cushing's disease is a rare debilitating endocrine disorder for which few prospective interventional studies have been done. We report results of the first phase 3 trial assessing long-acting intramuscular pasireotide in patients with Cushing's disease. METHODS In this phase 3 clinical trial we recruited patients aged 18 years or older with persistent, recurrent, or de-novo (non-surgical candidates) Cushing's disease who had a mean urinary free cortisol (mUFC) concentration (from three 24 h samples) of 1·5-5·0 times the upper limit of normal (ULN), a normal or greater than normal morning plasma adrenocorticotropic hormone concentration, and a pituitary source of Cushing's syndrome, from 57 sites across 19 countries. Exclusion criteria included previous pasireotide treatment, mitotane therapy within 6 months, and pituitary irradiation within 10 years. We randomly allocated patients 1:1 (block size of four) using an interactive-response-technology system to intramuscular pasireotide 10 mg or 30 mg every 4 weeks for 12 months (in the core phase). We stratified randomisation by screening mUFC concentration (1·5 to <2·0 × ULN and 2·0-5·0 × ULN). The dose could be uptitrated (from 10 mg to 30 mg or from 30 mg to 40 mg) at month 4 if the mUFC concentration was greater than 1·5 × ULN, and at month 7, month 9, or month 12 if the mUFC concentration was greater than 1·0 × ULN. Investigators, patients, site personnel, and those assessing outcomes were masked to dose group allocation. The primary endpoint was the proportion of patients in each group with an mUFC concentration of less than or equal to the ULN at month 7. Efficacy analyses were based on intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01374906. FINDINGS Between Dec 28, 2011, and Dec 9, 2014, we randomly allocated 150 patients to receive pasireotide 10 mg (74 [49%] patients) or 30 mg (76 [51%] patients). The primary efficacy endpoint was met by 31 (41·9% [95% CI 30·5-53·9]) of 74 patients in the 10 mg group and 31 (40·8% [29·7-52·7]) of 76 in the 30 mg group. The most common adverse events were hyperglycaemia (36 [49%] in the 10 mg group and 36 [47%] in the 30 mg group), diarrhoea (26 [35%] and 33 [43%]), cholelithiasis (15 [20%] and 34 [45%]), diabetes mellitus (14 [19%] and 18 [24%]), and nausea (15 [20%] and 16 [21%]). Serious adverse events suspected to be study drug related were reported in eight (11%) patients in the 10 mg group and four (5%) in the 30 mg group. Two (3%) patients in the 30 mg group died during the study (pulmonary artery thrombosis and cardiorespiratory failure); neither death was judged to be related to the study drug. INTERPRETATION Long-acting pasireotide normalised mUFC concentration in about 40% of patients with Cushing's disease at month 7 and had a similar safety profile to that of twice-daily subcutaneous pasireotide. Long-acting pasireotide is an efficacious treatment option for some patients with Cushing's disease who have persistent or recurrent disease after initial surgery or are not surgical candidates, and provides a convenient monthly administration schedule. FUNDING Novartis Pharma AG.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(17)30326-1

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 162

Metadata

Authors
Lacroix, A., Gu, F., Gallardo, W., Pivonello, R., Yu, Y., Witek, P., Boscaro, M., Salvatori, R., Yamada, M., Tauchmanova, L., Roughton, M., Ravichandran, S., Petersenn, S., Biller, B. M. K., Newell-Price, J., Arnaldi, G., Asha, H. S., Bandgar, T., Barkan, A., Biering, H., Bex, M., Bolanowski, M., Bronstein, M. D., Brue, T., Bruera, D., Cavagnini, F., Comlekci, A., De Block, C., Delibasi, T., Fajardo-Montañana, C., Feelders, R. A., Fleseriu, M., Gadelha, M. R., Geer, E. B., Heaney, A., Houde, G., Ichihara, A., Imran, S. A., Ioachimescu, A., Kadioglu, P., Li, Y., Loli, P., Nishiyama, M., Rozhinskaya, L., Ruchala, M., Saitoh, Y., Schöfl, C., Schopohl, J., Shimatsu, A., Shimizu, C., Snabboon, T., Snyder, P., Suzaki, N., Tabarin, A., Takahashi, Y., Britto, S. T., T'Sjoen, G., Vantyghem, M.-C., Velkeniers, B., Webb, S., & Yamada, S.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2018-01
Volume
6
Issue
1
Pages
17-26
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2763024200
Cited by
162
References
6
FWCI
10.02
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. https://app.cochat.ai/papers/10.1016/s2213-8587(17)30326-1
The paper
Lacroix, A., Gu, F., Gallardo, W., Pivonello, R., Yu, Y., Witek, P., Boscaro, M., Salvatori, R., Yamada, M., Tauchmanova, L., Roughton, M., Ravichandran, S., Petersenn, S., Biller, B. M. K., Newell-Price, J., Arnaldi, G., Asha, H. S., Bandgar, T., Barkan, A., . . . Yamada, S. (2018). Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(17)30326-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.